
PURPOSE Blood-based multicancer detection (MCD) tests are rapidly emerging in clinical practice, offering the potential to detect cancers-including those without established screening modalities-through a single assay. Their expanding commercial availability and growing patient awareness have propelled early clinical adoption despite limited evidence on effectiveness. METHODS This special report synthesizes the current landscape of MCD testing and examines the implications for primary care physicians (PCPs), who are often the first clinicians patients approach about these new technologies. RESULTS Evidence supporting MCD testing remains immature. A recent systematic review indicates insufficient data regarding mortality benefit, cancer detection outcomes, or quality- of-life impact. Despite this, MCD use is increasing through industry partnerships and health-system-driven implementation programs. Early adopters-including large health systems and cancer centers-have developed navigation pathways, diagnostic follow-up resources, and registries to support real-world evidence generation. Qualitative research with PCPs and physician leaders reveals recurrent concerns: patient-driven demand, insufficient practice guidelines, unclear diagnostic pathways, cost and equity challenges, and malpractice risk. Historical experience with prostate specific antigen (PSA) screening underscores the potential for a de facto standard of care to emerge ahead of robust evidence. CONCLUSION Primary care physicians face significant informational, procedural, and medicolegal uncertainty as MCD tests proliferate. Responsible integration will require coordinated evidence generation, including contributions from primary care practices. Until stronger evidence emerges, shared decision making (SDM) remains essential for navigating the promise and pitfalls of MCD testing in routine practice. PRIMARY: care physicians are confronting MCD testing issues ahead of evidence, requiring preparedness for patient-driven inquiries, clear SDM practices, and participation in evidence-generation.
We examined the effect of a rare Midwestern dust storm on pediatric allergic morbidity in a Chicago, Illinois primary care setting. As climate and land-use changes expand the geographic range of dust storm activity, primary care clinicians will increasingly encounter environmentally triggered asthma and allergy exacerbations. We performed a retrospective analysis of daily clinic visits before and after the May 16, 2025 dust storm and observed an increase in allergy-related visits, with a significant increase in the first 3 days after the storm. Visit diagnoses included eczema, asthma/reactive airway disease, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, and seasonal allergies. By focusing on primary care rather than emergency department visits, this work highlights the broader burden of dust-related allergic morbidity in the pediatric population. These findings underscore the need for primary care preparedness and community-level mitigation strategies as extreme weather events become more frequent.